Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Published byΝεφέλη Βιτάλη Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic."— Presentation transcript:

1 Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK
Figure 3 | Societal costs for the care of patients with chronic kidney disease in the UK. During the period 2009–2010, the costs involved in nonrenal replacement care almost equalled those for renal replacement care. MRSA, methicillin-resistant Staphylococcus aureus. Modified from Kerr, M. et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol. Dial. Transplant. 27 (Suppl. 3), iii73–iii80 (2012) by permission of the European Renal Association–European Dialysis and Transplantation Association. Modified from Kerr, M. et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol. Dial. Transplant. 27 (Suppl. 3), iii73–iii80 (2012) by permission of the European Renal Association–European Dialysis and Transplantation Association. Vanholder, R. et al. (2017) Reducing the costs of chronic kidney disease while delivering quality health care: a call to action Nat. Rev. Nephrol. doi: /nrneph

Download ppt "Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic."

Similar presentations

Fig. 1. Flow diagram of study participants and outcomes.

Fig. 1. Flow diagram of study participants and outcomes.
Fig. 1.  CsA blood concentration time curve according to the population model (dashed line), the actual measured CsA blood concentrations at t=0, 2 and.

Fig. 1.  CsA blood concentration time curve according to the population model (dashed line), the actual measured CsA blood concentrations at t=0, 2 and.
A.M. Thompson, T.G. Pickering  Kidney International 

A.M. Thompson, T.G. Pickering  Kidney International 
Renal Parenchymal Hypoxia, Hypoxia Response and the Progression of Chronic Kidney Disease Am J Nephrol 2008;28:998–1006 - DOI:10.1159/000146075 © 2008.

Renal Parenchymal Hypoxia, Hypoxia Response and the Progression of Chronic Kidney Disease Am J Nephrol 2008;28:998– DOI: / © 2008.
UK Renal Registry 15th Annual Report

UK Renal Registry 15th Annual Report
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.
Figure 4 Interplay between acute kidney injury (AKI),

Figure 4 Interplay between acute kidney injury (AKI),
Figure 6 Effects of adiponectin on podocyte function

Figure 6 Effects of adiponectin on podocyte function
Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.
Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.
Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.
Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Expression of coagulation protease receptors in renal cells
Figure 4 Interactions between adipose, the microbiome and kidney

Figure 4 Interactions between adipose, the microbiome and kidney
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 1 Mechanisms of kidney injury in the setting of obesity
Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Physiological changes in the renal system in pregnancy
Figure 2 Proinflammatory mechanisms in CKD

Figure 2 Proinflammatory mechanisms in CKD
Figure 1 Circadian changes in energy metabolism and immune responses in CKD Figure 1 | Circadian changes in energy metabolism and immune responses in CKD.

Figure 1 Circadian changes in energy metabolism and immune responses in CKD Figure 1 | Circadian changes in energy metabolism and immune responses in CKD.
Figure 1 Role of the kidney in glucose homeostasis

Figure 1 Role of the kidney in glucose homeostasis

Similar presentations

Ads by Google